DK1718967T3 - Metoder til at detektere Lp-PLA2 aktivitet - Google Patents

Metoder til at detektere Lp-PLA2 aktivitet

Info

Publication number
DK1718967T3
DK1718967T3 DK05712595.7T DK05712595T DK1718967T3 DK 1718967 T3 DK1718967 T3 DK 1718967T3 DK 05712595 T DK05712595 T DK 05712595T DK 1718967 T3 DK1718967 T3 DK 1718967T3
Authority
DK
Denmark
Prior art keywords
detecting
methods
pla2 activity
pla2
activity
Prior art date
Application number
DK05712595.7T
Other languages
Danish (da)
English (en)
Inventor
Robert L Wolfert
Nam Kim
Xiaozhu Duan
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Application granted granted Critical
Publication of DK1718967T3 publication Critical patent/DK1718967T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
DK05712595.7T 2004-02-03 2005-02-03 Metoder til at detektere Lp-PLA2 aktivitet DK1718967T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54158304P 2004-02-03 2004-02-03
PCT/US2005/003211 WO2005074604A2 (en) 2004-02-03 2005-02-03 METHODS OF DETECTING Lp-PLA2 ACTIVITY

Publications (1)

Publication Number Publication Date
DK1718967T3 true DK1718967T3 (da) 2013-06-03

Family

ID=34837507

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05712595.7T DK1718967T3 (da) 2004-02-03 2005-02-03 Metoder til at detektere Lp-PLA2 aktivitet

Country Status (6)

Country Link
US (1) US20070281323A1 (enExample)
EP (2) EP2280282A1 (enExample)
JP (2) JP5155564B2 (enExample)
DK (1) DK1718967T3 (enExample)
ES (1) ES2416344T3 (enExample)
WO (1) WO2005074604A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1633864E (pt) 2003-05-28 2010-06-24 Glaxo Group Ltd Ensaio de actividade de lp-pla2 de alta produtividade
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
ES2535640T3 (es) * 2008-07-18 2015-05-13 Boston Medical Center Corporation Diagnósticos para nefropatía membranosa
EP2246440A1 (en) * 2009-04-29 2010-11-03 Aterovax Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample
EP2588111A1 (en) * 2010-07-02 2013-05-08 BG Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
CN102692507B (zh) * 2011-07-29 2015-09-16 南京诺尔曼生物技术有限公司 脂蛋白相关磷脂酶a2(lppla2)测定试剂盒(胶乳增强免疫比浊法)
CN103048457B (zh) * 2012-11-27 2014-12-17 同昕生物技术（北京）有限公司 心肌梗死预警胶体金试剂盒及其制备方法
US20140283157A1 (en) * 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
CN104237517B (zh) * 2013-06-18 2016-05-18 深圳市安群生物工程有限公司 检测人Lp-PLA2蛋白的荧光免疫层析试纸及其制备方法
US20150086999A1 (en) * 2013-09-24 2015-03-26 Thomas D. Schaal Long shelf-life kits and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase a2
CN103792353B (zh) * 2013-10-17 2015-07-15 武汉生之源生物科技有限公司 一种脂蛋白相关磷脂酶a2含量检测试剂盒及其制备方法
WO2015058158A1 (en) * 2013-10-18 2015-04-23 Diadexus, Inc. METHOD FOR DETECTION OF LIPOPROTEIN-SPECIFIC Lp-PLA2 ASSOCIATION
EP3258269B1 (en) 2015-02-10 2019-06-05 Shenzhen New Industries Biomedical Engineering Co. Ltd. Reagent kit used for detecting lipoprotein-associated phospholipase a2, and preparation method and application for reagent kit
CN104634970B (zh) * 2015-02-10 2017-04-05 深圳市新产业生物医学工程股份有限公司 用于检测脂蛋白相关磷脂酶a2的试剂盒及其制备和应用
CN104820097A (zh) * 2015-05-22 2015-08-05 北京协和洛克生物技术有限责任公司 一种定量检测样本中脂蛋白磷脂酶a2浓度的液态芯片试剂盒及其制备方法
US11237167B2 (en) * 2017-01-24 2022-02-01 Cleveland Heartlab, Inc. Lp-PLA2 assays and composition with detergent
CN109917131B (zh) * 2019-03-26 2021-12-17 苏州博源医疗科技有限公司 一种脂蛋白磷脂酶a2检测试剂及其制备和使用方法
CN111175242A (zh) * 2020-03-17 2020-05-19 湖南新大陆生物技术有限公司 一种脂蛋白磷脂酶a2检测试剂盒及其应用
CN111662387A (zh) * 2020-07-14 2020-09-15 重庆中元汇吉生物技术有限公司 抗人脂蛋白相关磷脂酶a2单克隆抗体及其应用
JP7819983B1 (ja) * 2025-01-09 2026-02-25 学校法人松山大学 酵素の検出方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4925788A (en) 1986-10-24 1990-05-15 Immunicon Corporation Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
US5108933A (en) 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5186827A (en) 1991-03-25 1993-02-16 Immunicon Corporation Apparatus for magnetic separation featuring external magnetic means
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0590327B1 (en) 1992-09-11 2003-04-09 F. Hoffmann-La Roche Ag Detection of nucleic acids in blood
AU670108B2 (en) * 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995000649A1 (en) 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
US5656431A (en) 1993-10-06 1997-08-12 Icos Corporation Platelet-activating factor acetylhydrolase
US5847088A (en) * 1993-10-06 1998-12-08 Icos Corporation Antibodies specific for platelet-activating factor acetylhydrolase
US5977308A (en) 1993-10-06 1999-11-02 Icos Corporation Platelet-activating factor acetylhydrolase
EP1096016B1 (en) 1993-10-06 2006-01-11 Icos Corporation Platelet-activating factor acetylhydrolase
EP0929694A4 (en) 1996-03-15 2002-05-02 Penn State Res Found DETECTION OF TUMOR-RELATED EXTRACELLULAR NUCLEIC ACID USING PLASMA OR BLOOD SERUM USING NUCLEIC ACID AMPLIFICATION TESTS
US6630301B1 (en) 1997-03-14 2003-10-07 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO1999042830A1 (en) * 1998-02-23 1999-08-26 Diadexus Llc Methods using pla2 as a marker of metastases and for the diagnosis of selected cancers
JP2002528084A (ja) 1998-10-28 2002-09-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 固定化金属アフィニティークロマトグラフィーを用いる低密度リポタンパク質関連ホスホリパーゼａ２の精製方法
CN1331700A (zh) 1998-11-16 2002-01-16 基因纬生物技术公司 通过禽类中使用多核苷酸疫苗接种生成抗体的方法
JP4220603B2 (ja) 1998-12-02 2009-02-04 アルフレッサファーマ株式会社 血小板活性化因子アセチルヒドロラーゼ活性の測定方法
US6960449B2 (en) 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
JP2002051164A (ja) * 2000-05-24 2002-02-15 Victor Co Of Japan Ltd 音声コンテンツ試聴システム及びシステムサーバ並びに携帯電話機
EP1318154B1 (de) 2001-12-07 2004-06-16 SIRS-Lab GmbH Verbindungen zur Bestimmung der Aktivität von Phospholipase A2
PT1633864E (pt) 2003-05-28 2010-06-24 Glaxo Group Ltd Ensaio de actividade de lp-pla2 de alta produtividade

Also Published As

Publication number Publication date
EP1718967A2 (en) 2006-11-08
EP1718967B1 (en) 2013-04-24
JP2007523644A (ja) 2007-08-23
EP1718967A4 (en) 2008-03-05
WO2005074604A2 (en) 2005-08-18
JP5155564B2 (ja) 2013-03-06
JP2011177182A (ja) 2011-09-15
US20070281323A1 (en) 2007-12-06
WO2005074604A3 (en) 2005-12-29
EP2280282A1 (en) 2011-02-02
ES2416344T3 (es) 2013-07-31

Similar Documents

Publication Publication Date Title
DK3524150T3 (da) Transkutan analytsensor
DE602005022454D1 (de) Enzymatische nachweistechniken
ATE446090T1 (de) Thiadiazolidinone als gsk3-inhibitoren
DE602005024280D1 (de) Objektdetektor
CY2016009I2 (el) Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
EP1736763A4 (en) ANALISEUR
DE602005003147D1 (de) Messsystem
PL2387014T3 (pl) System do wykrywania wielu zagrożeń
DK2433943T3 (da) Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet
DK1598097T3 (da) Byggesystem
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
EP1752407A4 (en) LIFT SYSTEM
NO20042409D0 (no) System and method for presence detection
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
EP1795898A4 (en) ANALYSIS DEVICE
EP1767204A4 (en) LIPASE INHIBITORS
DE502005000300D1 (de) Tastkopf
DE602005020180D1 (de) Verbessertes messsystem
DE602004031602D1 (de) Vorverstärker
FI20040165L (fi) Järjestelmä kunnonvalvontaa varten
FI20045242A0 (fi) Tiedon arviointi
FI20050681A0 (fi) Paikoitusmenetelmä
SE0500634L (sv) Övervakningssystem
EP1832992A4 (en) GENOME ANALYSIS METHOD
FI20041066A0 (fi) Menetelmä ja järjestely kosketuksen tunnistamiseksi